Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions

BACKGROUND: Gefitinib, erlotinib and afatinib provide remarkable response rates and progression-free survival compared to platinum-based chemotherapy in patients with non-small cell lung cancer harboring epidermal growth factor receptor-activating mutations, and are therefore standard first-line tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuan, Feng-Che, Li, Shih-Hong, Wang, Chih-Liang, Lin, Meng-Hung, Tsai, Ying-Huang, Yang, Cheng-Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352060/
https://www.ncbi.nlm.nih.gov/pubmed/27935868
http://dx.doi.org/10.18632/oncotarget.13815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352060/
https://www.ncbi.nlm.nih.gov/pubmed/27935868
http://dx.doi.org/10.18632/oncotarget.13815

Ejemplares similares